Cadrenal Therapeutics Q2 net loss narrows 9.39% to $3.3 million
Reuters2026/08/13 20:24- Cadrenal posted a Q2 net loss of USD 3.32 million, narrowing from USD 3.67 million a year earlier.
- Operating loss narrowed to USD 3.34 million as total operating expenses fell to USD 3.34 million from USD 3.73 million.
- R&D spending dropped to USD 705,151 from USD 1.08 million; G&A edged down to USD 2.63 million from USD 2.66 million.
- Cash and cash equivalents were about USD 4.2 million in early August; runway expected through Q1 2027 under the current plan.
- Launched a structured partnering process for CAD-1005, frunexian and tecarfarin following Phase 2 CAD-1005 data showing >25% thrombotic-event reduction.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
UBS lowers Ciena target price to $394
EUR/USD Price Forecast: Holds key 100-day SMA at start of the US CPI week
Malaysia Govt Spending Plan Could Help 99 Speed Mart Retail -- Market Talk
Paying the price for supporting the yen? Japan's foreign reserves fell by $87.8 billions in August, possibly due to selling US Treasuries for funding.
Japanese authorities may have used part of their foreign exchange reserves, including foreign securities such as U.S. Treasury bonds, over the past month to fund record-sized foreign exchange intervention operations.
Crypto prices
More
